Apolipoprotein CIII links dyslipidemia with atherosclerosis.
about
Chronic hepatitis C virus infection and lipoprotein metabolismEffect of dietary saturated fatty acids on HNF-4α DNA binding activity and ApoCIII mRNA in sedentary rat liverModeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platformMass spectrometric identification of aberrantly glycosylated human apolipoprotein C-III peptides in urine from Schistosoma mansoni-infected individualsLevels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East ChinaBeef in an Optimal Lean Diet study: effects on lipids, lipoproteins, and apolipoproteins.Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart diseaseMdm2 is a novel activator of ApoCIII promoter which is antagonized by p53 and SHP inhibitionLPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialAssociation between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study.Correlation between mesenteric fat thickness and serum apolipoproteins in patients with peripheral arterial occlusive disease.Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in menIdentification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan.D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC Study.Modifications in rat plasma proteome after remote ischemic preconditioning (RIPC) stimulus: identification by a SELDI-TOF-MS approachDiscrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithmCharacterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fetal systemic inflammatory response.Molecular biology of atherosclerosis.Endothelial dysfunction in metabolic and vascular disorders.Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.Biological factors in plasma from diabetes mellitus patients enhance hyperglycaemia and pulsatile shear stress-induced endothelial cell apoptosis.Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.Extracorporeal Treatment in Severe Hypertriglyceridemia-Induced Pancreatitis.Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks.Apolipoprotein C-III in the high-density lipoprotein proteome of cerebral lacunar infarction patients impairs its anti-inflammatory function.Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C.ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.N-(3-Benzoylphenyl)-1H-Indole-2-Carboxamide decreases triglyceride levels by downregulation of Apoc3 gene expression in acute hyperlipidemic rat model.LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans.Linking diabetes and atherosclerosis
P2860
Q26784234-2153A7A3-0889-48A7-884B-6F480AF18C94Q28579421-9DB074C1-9B02-46B4-A156-C0F0CB417BFAQ28743135-9652E4B6-780F-4E0B-B385-249EC12FD737Q33812839-E6169669-40FF-4A16-83CE-652FAE60030FQ34608381-55F7B14C-82B3-42D2-8C6C-F0515FDCB373Q34955753-44347847-0DD6-4DF6-AA8E-00488AA45614Q35565455-B89189EA-DFBC-4D02-B812-4B6F15AA5501Q35615296-CEADA99C-5AD1-4E36-B9E6-2C5AF1FB011FQ35628166-3AE85A86-192B-48EF-AF96-4150E96BC8BEQ35675337-CECC9CA3-772F-46CA-8FB4-3802BECA29B3Q35747811-E409F89D-2503-4A4A-8574-F1CEC946600FQ36019971-EF14743C-1817-4362-B71F-0E617A03BCB6Q36069778-F4822950-CADE-442F-A0F3-42CD13CB46EFQ36335132-A512F12D-0A9E-4497-BD1A-274CF62B6268Q36377367-640163AB-DEBC-4BAD-ADE7-5DB32E802233Q36527075-ED572007-9C06-48A3-B78C-B2A4331ADE7BQ36528525-AC2BE4FC-23DE-4766-B2F0-22F3376C5BE9Q36554649-C9165305-5DA7-4492-A6CB-A3C2B3EEB232Q37331224-0FC875CE-EA69-47F9-AE7B-DCB594FDCDABQ37472996-DF79C7FD-C7D4-41D6-99BE-3A32F621CC73Q37542168-BC5BBA8D-0194-4D6B-9815-FB3DA6ABF25EQ37612440-914DECEE-FE23-4380-A01B-6B4628ADBE28Q38125279-A9435157-1EEF-4970-9BA4-DCDFD5C9BCBBQ38200828-9919A411-EDFC-4542-A784-789E6A12004DQ38219481-5B7E0D6D-BD25-4DEF-86A1-6C013C1B944EQ38260532-BC1B5801-D36C-4042-8EC0-D430301769A2Q39014134-9941925C-FE43-4F66-A5B3-A33B7D3EFACAQ39826326-BEC7B282-7FD5-46EA-8A9A-0FF6A21C7EA2Q41103518-2251121B-9EE7-4F2C-8341-961836AC7BC0Q43225362-0C7DC9C6-9D6C-48B9-8EB7-ABD40D9E674BQ43245615-3F37A5E1-501A-472A-B25A-FB2B10BD8849Q47152874-22756D32-985F-4F9A-84A9-2745835686F4Q50001089-1E4BDB59-5363-48EC-83FD-75C0B73870B6Q50075898-A755DBE1-FBD1-4032-A29D-1E65CDF93143Q51113879-A1B84C23-14F3-440A-999B-C8E5E4E76DE9Q55010234-0C7A404B-5422-4813-BAF9-D710854B3010Q57182351-F0C1256B-E590-42BD-BA78-344CC95A854D
P2860
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@en
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@nl
type
label
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@en
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@nl
prefLabel
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@en
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@nl
P356
P1476
Apolipoprotein CIII links dyslipidemia with atherosclerosis.
@en
P2093
Akio Kawakami
Masayuki Yoshida
P356
10.5551/JAT.E607
P577
2009-03-05T00:00:00Z